Page 315 - Drug Class Review

Drug Effectiveness Review Project

Drugs Authors: Grossberg et al. 92 Country: NR (authors from Switzerland and the US; trials not reported in detail) To conduct a pharmacodynamic analysis of potential drug interactions between RIV and other medications commonly prescribed in the elderly AD population Study design: Post-hoc analysis of data from 4 RCTs placebo rivastigmine N/A 1 to 12 mg/d 6 months 6 months 763 1,696 Patients randomized in placebo-controlled trials of RIV Page 188 of 205

Alzheimer Year: 2000 Novartis Setting: NR Sample size: 2,459 NR Yes

Final Report Update 1 Subgroups STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs